Terkko Navigator / Handbook of Experimental Pharmacology

Kappa Opioid Agonist-Induced Diuresis: Characteristics, Mechanisms, and Beyond.

The Epigenome in Atherosclerosis.

Brain Distribution of Drugs: Brain Morphology, Delivery Routes, and Species Differences.

Tissue Engineering for Musculoskeletal Regeneration and Disease Modeling.

Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands.

Regulatory Non-coding RNAs in Atherosclerosis.

Novel Treatment Approaches for Brain Tumour from a Blood-Brain Barrier Perspective.

The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.

Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis.

Does GEC1 Enhance Expression and Forward Trafficking of the Kappa Opioid Receptor (KOR) via Its Ability to Interact with NSF Directly?

Antinociceptive Effects of Kappa-Opioid Receptor Agonists.

Skin Disease Models In Vitro and Inflammatory Mechanisms: Predictability for Drug Development.

In Vivo Studies of Drug BBB Transport: Translational Challenges and the Role of Brain Imaging.

Biosensors Monitor Ligand-Selective Effects at Kappa Opioid Receptors.

Correction to: Blood Pressure-Lowering Therapy.

Novel Adipose Tissue Targets to Prevent and Treat Atherosclerosis.

Inhibition of Myeloperoxidase.

Standardised Reconstructed Skin Models in Toxicology and Pharmacology: State of the Art and Future Development.

Drug Delivery Strategies to Overcome the Blood-Brain Barrier (BBB).

Immunocompetent Human Intestinal Models in Preclinical Drug Development.

Smooth Muscle Cell-Proteoglycan-Lipoprotein Interactions as Drivers of Atherosclerosis.

Correction to: Use of Botulinum Toxin in Ophthalmology.

Correction to: The Use of Botulinum Toxin in the Management of Headache Disorders.

KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.

Correction to: The Use of Botulinum Toxin for Treatment of the Dystonias.

Correction to: The Use of Botulinum Toxin for Treatment of Spasticity.

Correction to: Botulinum Toxin and Pain.

Antipruritic Effects of Kappa Opioid Receptor Agonists: Evidence from Rodents to Humans.

Correction to: The Use of Botulinum Toxin for Treatment of Depression.

Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.

Brain Distribution of Drugs: Pharmacokinetic Considerations.

Structure and Function of the Blood-Brain Barrier (BBB).

Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective.

Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients.

Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders.

Molecular Genetics of Kappa Opioids in Pain and Itch Sensations.

Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology.

Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers.

Epilepsy and Alterations of the Blood-Brain Barrier: Cause or Consequence of Epileptic Seizures or Both?

Human-Derived In Vitro Models Used for Skin Toxicity Testing Under REACh.

Engineered Heart Muscle Models in Phenotypic Drug Screens.

Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection.

Transport Studies Using Blood-Brain Barrier In Vitro Models: A Critical Review and Guidelines.

The Central Regulation of Bone Mass: Genetic Evidence and Molecular Bases.

How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.

Clinical Pharmacology of Botulinum Toxin Drugs.

Structural and Metabolic Assessment of Bone.

Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.

Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.

Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.